SI3902547T1 - Inhibitorji CSF1R za uporabo pri zdravljenju raka - Google Patents
Inhibitorji CSF1R za uporabo pri zdravljenju rakaInfo
- Publication number
- SI3902547T1 SI3902547T1 SI201930651T SI201930651T SI3902547T1 SI 3902547 T1 SI3902547 T1 SI 3902547T1 SI 201930651 T SI201930651 T SI 201930651T SI 201930651 T SI201930651 T SI 201930651T SI 3902547 T1 SI3902547 T1 SI 3902547T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treating cancer
- csf1r inhibitors
- csf1r
- inhibitors
- cancer
- Prior art date
Links
- 101150053778 CSF1R gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786105P | 2018-12-28 | 2018-12-28 | |
| US201962926341P | 2019-10-25 | 2019-10-25 | |
| US201962933830P | 2019-11-11 | 2019-11-11 | |
| EP19842712.2A EP3902547B1 (en) | 2018-12-28 | 2019-12-23 | Csf1r inhibitors for use in treating cancer |
| PCT/US2019/068311 WO2020139828A1 (en) | 2018-12-28 | 2019-12-23 | Csf1r inhibitors for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3902547T1 true SI3902547T1 (sl) | 2024-02-29 |
Family
ID=69191281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930651T SI3902547T1 (sl) | 2018-12-28 | 2019-12-23 | Inhibitorji CSF1R za uporabo pri zdravljenju raka |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11103507B2 (sl) |
| EP (2) | EP3902547B1 (sl) |
| JP (1) | JP2022516090A (sl) |
| KR (1) | KR20210119411A (sl) |
| AU (1) | AU2019416117B2 (sl) |
| BR (1) | BR112021012812A2 (sl) |
| CA (1) | CA3124112A1 (sl) |
| DK (1) | DK3902547T3 (sl) |
| ES (1) | ES2964489T3 (sl) |
| FI (1) | FI3902547T3 (sl) |
| HR (1) | HRP20231478T1 (sl) |
| IL (1) | IL284199A (sl) |
| LT (1) | LT3902547T (sl) |
| MX (1) | MX2021007927A (sl) |
| PL (1) | PL3902547T3 (sl) |
| PT (1) | PT3902547T (sl) |
| RS (1) | RS64993B1 (sl) |
| SG (1) | SG11202105747XA (sl) |
| SI (1) | SI3902547T1 (sl) |
| TW (1) | TW202041218A (sl) |
| WO (1) | WO2020139828A1 (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3902547T (lt) * | 2018-12-28 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitoriai, skirti panaudoti vėžio gydymui |
| DK3966207T3 (da) | 2019-05-10 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| AU2020297422B2 (en) | 2019-06-17 | 2024-03-21 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| PL4084778T3 (pl) | 2019-12-30 | 2024-03-04 | Deciphera Pharmaceuticals, Llc | Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania |
| US20230382871A1 (en) * | 2020-09-23 | 2023-11-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Csf1r kinase inhibitor and use thereof |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5794047A (en) | 1980-12-01 | 1982-06-11 | Ricoh Co Ltd | Novel disazo compound and preparation of the same |
| RS94703A (en) | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| CN100415720C (zh) | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| WO2006136837A2 (en) | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
| WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008140895A1 (en) | 2007-04-20 | 2008-11-20 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| EP2254889B1 (en) | 2008-02-28 | 2012-12-19 | Merck Patent GmbH | Protein kinase inhibitors and use thereof |
| JP5444365B2 (ja) | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
| JP5795630B2 (ja) | 2010-04-29 | 2015-10-14 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 |
| CA2800998A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| BR112014012407A2 (pt) | 2011-11-22 | 2017-06-06 | Deciphera Pharmaceuticals Llc | amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2014145004A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| CA2903288C (en) | 2013-03-15 | 2021-09-21 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2014145029A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| JP6165314B2 (ja) | 2013-03-15 | 2017-07-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| WO2018222173A1 (en) | 2017-05-30 | 2018-12-06 | Deciphera Pharmaceuticals, Inc. | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
| SG11202007287XA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of mastocytosis |
| LT3902547T (lt) * | 2018-12-28 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitoriai, skirti panaudoti vėžio gydymui |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| DK3966207T3 (da) | 2019-05-10 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf |
-
2019
- 2019-12-23 LT LTEPPCT/US2019/068311T patent/LT3902547T/lt unknown
- 2019-12-23 SI SI201930651T patent/SI3902547T1/sl unknown
- 2019-12-23 CA CA3124112A patent/CA3124112A1/en active Pending
- 2019-12-23 DK DK19842712.2T patent/DK3902547T3/da active
- 2019-12-23 FI FIEP19842712.2T patent/FI3902547T3/fi active
- 2019-12-23 MX MX2021007927A patent/MX2021007927A/es unknown
- 2019-12-23 KR KR1020217024011A patent/KR20210119411A/ko unknown
- 2019-12-23 HR HRP20231478TT patent/HRP20231478T1/hr unknown
- 2019-12-23 PL PL19842712.2T patent/PL3902547T3/pl unknown
- 2019-12-23 ES ES19842712T patent/ES2964489T3/es active Active
- 2019-12-23 AU AU2019416117A patent/AU2019416117B2/en active Active
- 2019-12-23 JP JP2021537759A patent/JP2022516090A/ja active Pending
- 2019-12-23 SG SG11202105747XA patent/SG11202105747XA/en unknown
- 2019-12-23 WO PCT/US2019/068311 patent/WO2020139828A1/en active Application Filing
- 2019-12-23 EP EP19842712.2A patent/EP3902547B1/en active Active
- 2019-12-23 BR BR112021012812A patent/BR112021012812A2/pt unknown
- 2019-12-23 PT PT198427122T patent/PT3902547T/pt unknown
- 2019-12-23 US US16/725,282 patent/US11103507B2/en active Active
- 2019-12-23 RS RS20231149A patent/RS64993B1/sr unknown
- 2019-12-23 EP EP23195809.1A patent/EP4303583A3/en active Pending
- 2019-12-27 TW TW108148219A patent/TW202041218A/zh unknown
-
2021
- 2021-06-20 IL IL284199A patent/IL284199A/en unknown
- 2021-06-25 US US17/358,137 patent/US11679110B2/en active Active
-
2023
- 2023-04-28 US US18/140,942 patent/US20230414614A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124112A1 (en) | 2020-07-02 |
| EP4303583A2 (en) | 2024-01-10 |
| US11679110B2 (en) | 2023-06-20 |
| US11103507B2 (en) | 2021-08-31 |
| IL284199A (en) | 2021-08-31 |
| BR112021012812A2 (pt) | 2021-12-07 |
| PL3902547T3 (pl) | 2024-02-26 |
| RS64993B1 (sr) | 2024-01-31 |
| TW202041218A (zh) | 2020-11-16 |
| EP3902547A1 (en) | 2021-11-03 |
| US20200253973A1 (en) | 2020-08-13 |
| KR20210119411A (ko) | 2021-10-05 |
| AU2019416117B2 (en) | 2024-05-02 |
| WO2020139828A1 (en) | 2020-07-02 |
| DK3902547T3 (da) | 2023-12-18 |
| HRP20231478T1 (hr) | 2024-04-26 |
| EP3902547B1 (en) | 2023-09-20 |
| ES2964489T3 (es) | 2024-04-08 |
| LT3902547T (lt) | 2024-01-25 |
| MX2021007927A (es) | 2021-10-26 |
| SG11202105747XA (en) | 2021-07-29 |
| US20220143018A1 (en) | 2022-05-12 |
| FI3902547T3 (fi) | 2023-12-05 |
| US20230414614A1 (en) | 2023-12-28 |
| EP4303583A3 (en) | 2024-03-27 |
| AU2019416117A1 (en) | 2021-06-17 |
| CN113453684A (zh) | 2021-09-28 |
| PT3902547T (pt) | 2023-12-04 |
| JP2022516090A (ja) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284199A (en) | CSF1R inhibitors for cancer treatment | |
| IL282663A (en) | BT1718 for use in cancer treatment | |
| EP3432927A4 (en) | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL255189B2 (en) | A combination of RAD1901 and a CDK4/6 inhibitor for use in cancer therapy | |
| HK1249469A1 (zh) | 用RORγ抑制劑治療癌症的方法 | |
| IL268430A (en) | Methods for treating cancer using hsp90 inhibitors | |
| IL272088A (en) | A DHODH inhibitor for use in the treatment of hematological cancer | |
| IL274445A (en) | Adenosine pathway inhibitors for cancer treatment | |
| EP3131552A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| IL280158A (en) | Methods of treating cancer with the PI3K inhibitor, GDC-0077 | |
| RS61745B1 (sr) | Inhibitori farneziltransferaze za upotrebu u tretiranju kancera | |
| HK1256174A1 (zh) | 用於治療疼痛的 vap-1 抑制劑 | |
| PT3293201T (pt) | Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro | |
| IL280830A (en) | Bracelets for use in cancer treatment methods | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| IL285538A (en) | Combined therapies for use in cancer treatment | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| EP3131550A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| PT3813832T (pt) | Compostos para utilização na prevenção ou tratamento de cancro | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment |